SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "(AMNE:(Clinical Medicine)) srt2:(2000-2009)"

Sökning: (AMNE:(Clinical Medicine)) > (2000-2009)

  • Resultat 1-10 av 26494
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Ohlin, Andreas, et al. (författare)
  • Real-time PCR of the 16S-rRNA gene in the diagnosis of neonatal bacteraemia
  • 2008
  • Ingår i: Acta Paediatrica. - Oslo : Taylor & Francis. - 0803-5253 .- 1651-2227. ; 97:10, s. 1376-1380
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVE: To evaluate a real-time PCR assay for the diagnosis of neonatal bacteraemia. PATIENTS AND METHODS: Two hundred ninety-five plasma samples from 288 newborns with suspected neonatal sepsis were collected prospectively for the purpose of polymerase chain reaction (PCR)-based bacterial detection. A real-time PCR targeting the bacterial gene for 16S-rRNA gene combined with four specific probes designed to detect Gram-negative bacteria, Staphylococcus aureus and coagulase-negative staphylococci (CoNS) was developed. All samples positive in the universal PCR were further sequenced for bacterial identification. RESULTS: When applied to a material from 50 patients with positive blood culture and 245 patients with negative blood culture, the universal PCR showed a sensitivity of 42% (28-57), a specificity of 95% (92-97), a positive predictive value of 64% (45-80), and a negative predictive value of 89% (84-92) (95% confidence intervals in brackets). CONCLUSION: A new real-time PCR technique was for the first time applied to a well-defined prospectively and consecutively enrolled material of newborns with suspected sepsis, combining the benefits of real-time PCR with specific probes and sequencing. The method managed to detect bacteraemia with high specificity even though the sensitivity was low. Factors causing the low sensitivity are identified and further strategies to develop the method are described.
  •  
2.
  • Ruiz, Jonatan R., et al. (författare)
  • High cardiovascular fitness is associated with low metabolic risk score in children : the European Youth Heart Study
  • 2007
  • Ingår i: Pediatric Research. - Baltimore, Md : Williams and Wilkins Co. - 0031-3998 .- 1530-0447. ; 61:3, s. 350-355
  • Tidskriftsartikel (refereegranskat)abstract
    • The aim of the present study was to examine the associations of cardiovascular fitness (CVF) with a clustering of metabolic risk factors in children, and to examine whether there is a CVF level associated with a low metabolic risk. CVF was estimated by a maximal ergometer bike test on 873 randomly selected children from Sweden and Estonia. Additional measured outcomes included fasting insulin, glucose, triglycerides, HDLC, blood pressure, and the sum of five skinfolds. A metabolic risk score was computed as the mean of the standardized outcomes scores. A risk score <75th percentile was considered to indicate a low metabolic risk. CVF was negatively associated with clustering of metabolic risk factors in children. Receiver operating characteristic curve analysis showed a significant discriminatory accuracy of CVF in identifying the low/high metabolic risk in girls and boys (p < 0.001). The CVF level for a low metabolic risk was 37.0 and 42.1 mL/kg/min in girls and boys, respectively. These levels are similar to the health-related threshold values of CVF suggested by worldwide recognized organizations. In conclusion, the results suggest a hypothetical CVF level for having a low metabolic risk, which should be further tested in longitudinal and/or intervention studies. Abbreviations: AUC, area under the curve CVF, cardiovascular fitness ROC, receiver operating characteristic
  •  
3.
  •  
4.
  • Holmer, Helene, et al. (författare)
  • Nonfatal stroke, cardiac disease, and diabetes mellitus in hypopituitary patients on hormone replacement including growth hormone
  • 2007
  • Ingår i: Journal of Clinical Endocrinology and Metabolism. - : The Endocrine Society. - 1945-7197 .- 0021-972X. ; 92:9, s. 3560-3567
  • Tidskriftsartikel (refereegranskat)abstract
    • Context: The impact of long-term GH replacement on cerebrovascular and cardiovascular diseases and diabetes mellitus in hypopituitary patients is unknown. Objective: The incidence of nonfatal stroke and cardiac events, and prevalence of type 2 diabetes mellitus ( T2D) and cardioprotective medication were compared between cohorts of GH-deficient (GHD) patients and population controls. Design and Participants: The incidence of nonfatal stroke and cardiac events was estimated retrospectively from questionnaires in 750 GHD patients and 2314 matched population controls. A prevalence of T2D and cardioprotective medication was recorded at the distribution of questionnaires. Time since first pituitary deficiency to start of GH therapy was 4 and 2 yr, and time on GH therapy was 6 yr for GHD women and men, respectively. Results: Lifelong incidence of nonfatal stroke was tripled in GHD women and doubled in GHD men, but a decline was seen in both genders during periods after first pituitary hormone deficiency and GHD, during which most patients had GH therapy. The lifelong incidence of nonfatal cardiac events declined in GHD men during first pituitary hormone deficiency and GHD periods. GHD women had a higher prevalence of T2D and lipid-lowering medication, whereas GHD men had a higher prevalence of antihypertensive medication. Conclusions: The declined risks of nonfatal stroke in both genders and of nonfatal cardiac events in GHD men during periods on GH replacement may be caused by prescription of cardioprotective drugs and 6-yr GH replacement. GHD women had an increased prevalence of T2D, partly attributed to higher body mass index and lower physical activity.
  •  
5.
  • Lönnerholm, Gudmar, et al. (författare)
  • In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia.
  • 2009
  • Ingår i: Leukemia research. - Oxford : Elsevier BV. - 0145-2126 .- 1873-5835. ; 33:1, s. 46-53
  • Tidskriftsartikel (refereegranskat)abstract
    • Leukemic cells from 85 children with newly diagnosed precursor B-lineage ALL were tested for in vitro drug sensitivity to a panel of anti-cancer drugs. Minimal residual disease (MRD) was measured by RQ-PCR. There was a significant correlation between MRD day 29 and in vitro sensitivity to prednisolone (p<0.001) and doxorubicin (p=0.017), drugs administered during induction therapy. In patients with t(12;21) (n=20), in vitro sensitivity to doxorubicin was an independent factor for MRD <0.1% (p=0.031; R(2)=0.66). Thus, data show that in vitro drug sensitivity at diagnosis is correlated to cell kill during induction therapy as measured by MRD day 29.
  •  
6.
  • Osika, Walter, et al. (författare)
  • Sex differences in peripheral artery intima, media and intima media thickness in children and adolescents
  • 2009
  • Ingår i: Atherosclerosis. - Amsterdam : Elsevier. - 0021-9150 .- 1879-1484. ; 203:1, s. 172-177
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective Males have higher coronary heart disease (CHD) lifetime risk and increased magnitude of atherosclerosis, compared with women. Using very high-resolution ultrasound, we have shown that the intima thickness (IT) of radial and dorsal pedal arteries, measured separately from the media thickness (MT), increases with age. We wanted to test whether there is already a difference between the sexes in childhood for IT, MT and intima media thickness (IMT) in the radial and dorsal pedal arteries. Methods and results A total of 252 children (age 14.5 years S.D. ± 1.0 girls/boys 139/113) from two schools in Gothenburg, Sweden, participated in the study. The high-resolution (55 MHz) ultrasound measurements showed that boys had larger values than girls for the radial IT (0.057 ± 0.010 mm vs. 0.054 ± 0.008 mm, P = 0.007), MT (0.176 ± 0.033 vs. 0.153 ± 0.025, P = 0.031), IMT (0.232 ± 0.035 vs. 0.207 ± 0.026, P = 0.000), and for dorsal pedal artery MT (0.160 ± 0.039 vs. 0.149 ± 0.034, P = 0.022) and IMT (0.222 ± 0.041 vs. 0.209 ± 0.037, P = 0.016). Conclusion With this new very high-resolution ultrasound technique, we demonstrated in a large study population of children, that both intimal and medial arterial wall layers were thicker in boys than in girls. These findings may constitute an “early background” explaining why CHD starts sooner in men compared with women.
  •  
7.
  • Albertsson-Wikland, Kerstin, 1947, et al. (författare)
  • Dose-dependent effect of growth hormone on final height in children with short stature without growth hormone deficiency
  • 2008
  • Ingår i: Journal of Clinical Endocrinology and Metabolism. - : The Endocrine Society. - 0021-972X .- 1945-7197. ; 93:11, s. 4342-4350
  • Tidskriftsartikel (refereegranskat)abstract
    • CONTEXT: The effect of GH therapy in short non-GH-deficient children, especially those with idiopathic short stature (ISS), has not been clearly established owing to the lack of controlled trials continuing until final height (FH).OBJECTIVE: The aim of the study was to investigate the effect on growth to FH of two GH doses given to short children, mainly with ISS, compared with untreated controls.DESIGN AND SETTING: A randomized, controlled, long-term multicenter trial was conducted in Sweden.INTERVENTION: Two doses of GH (Genotropin) were administered, 33 or 67 microg/kg.d; control subjects were untreated.SUBJECTS: A total of 177 subjects with short stature were enrolled. Of these, 151 were included in the intent to treat (AllITT) population, and 108 in the per protocol (AllPP) population. Analysis of ISS subjects included 126 children in the ITT (ISSITT) population and 68 subjects in the PP (ISSPP) population.MAIN OUTCOME MEASURES: We measured FH sd score (SDS), difference in SDS to midparenteral height (diff MPHSDS), and gain in heightSDS.RESULTS: After 5.9+/-1.1 yr on GH therapy, the FHSDS in the AllPP population treated with GH vs. controls was -1.5+/-0.81 (33 microg/kg.d, -1.7+/-0.70; and 67 microg/kg.d, -1.4+/-0.86; P<0.032), vs. -2.4+/-0.85 (P<0.001); the diff MPHSDS was -0.2+/-1.0 vs. -1.0+/-0.74 (P<0.001); and the gain in heightSDS was 1.3+/-0.78 vs. 0.2+/-0.69 (P<0.001). GH therapy was safe and had no impact on time to onset of puberty. A dose-response relationship identified after 1 yr remained to FH for all growth outcome variables in all four populations.CONCLUSION: GH treatment significantly increased FH in ISS children in a dose-dependent manner, with a mean gain of 1.3 SDS (8 cm) and a broad range of response from no gain to 3 SDS compared to a mean gain of 0.2 SDS in the untreated controls. 
  •  
8.
  • Ludvigsson, Johnny, 1943-, et al. (författare)
  • GAD treatment and insulin secretion in recent-onset type 1 diabetes
  • 2008
  • Ingår i: New England Journal of Medicine. - Boston, Mass : Massachusetts medical society. - 0028-4793 .- 1533-4406. ; 359:18, s. 1909-1920
  • Tidskriftsartikel (refereegranskat)abstract
    • Background The 65-kD isoform of glutamic acid decarboxylase (GAD) is a major autoantigen in patients with type 1 diabetes mellitus. This trial assessed the ability of alum-formulated GAD (GAD-alum) to reverse recent-onset type 1 diabetes in patients 10 to 18 years of age. Methods We randomly assigned 70 patients with type 1 diabetes who had fasting C-peptide levels above 0.1 nmol per liter (0.3 ng per milliliter) and GAD autoantibodies, recruited within 18 months after receiving the diagnosis of diabetes, to receive subcutaneous injections of 20 μg of GAD-alum (35 patients) or placebo (alum alone, 35 patients) on study days 1 and 30. At day 1 and months 3, 9, 15, 21, and 30, patients underwent a mixed-meal tolerance test to stimulate residual insulin secretion (measured as the C-peptide level). The effect of GAD-alum on the immune system was also studied. Results Insulin secretion gradually decreased in both study groups. The study treatment had no significant effect on change in fasting C-peptide level after 15 months (the primary end point). Fasting C-peptide levels declined from baseline levels significantly less over 30 months in the GAD-alum group than in the placebo group (−0.21 vs. −0.27 nmol per liter [−0.62 vs. −0.81 ng per milliliter], P = 0.045), as did stimulated secretion measured as the area under the curve (−0.72 vs. −1.02 nmol per liter per 2 hours [−2.20 vs. −3.08 ng per milliliter per 2 hours], P = 0.04). No protective effect was seen in patients treated 6 months or more after receiving the diagnosis. Adverse events appeared to be mild and similar in frequency between the two groups. The GAD-alum treatment induced a GAD-specific immune response. Conclusions GAD-alum may contribute to the preservation of residual insulin secretion in patients with recent-onset type 1 diabetes, although it did not change the insulin requirement. (ClinicalTrials.gov number, NCT00435981.)
  •  
9.
  • Friberg, Örjan, et al. (författare)
  • Incidence, microbiological findings, and clinical presentation of sternal wound infections after cardiac surgery with and without local gentamicin prophylaxis
  • 2007
  • Ingår i: European Journal of Clinical Microbiology and Infectious Diseases. - Berlin : Springer. - 0934-9723 .- 1435-4373. ; 26:2, s. 91-97
  • Tidskriftsartikel (refereegranskat)abstract
    • Sternal wound infection (SWI) is a serious complication after cardiac surgery. In a previous randomized controlled trial, the addition of local collagen-gentamicin in the sternal wound before wound closure was found to significantly reduce the incidence of postoperative wound infections compared with the routine intravenous prophylaxis of isoxazolyl-penicillin only. The aims of the present study were to analyse the microbiological findings of the SWIs from the previous trial as well as to correlate these findings with the clinical presentation of SWI. Differences in clinical presentation of SWIs, depending on the causative agent, could be identified. Most infections had a late, insidious onset, and the majority of these were caused by staphylococci, predominantly coagulase-negative staphylococci. The clinically most fulminant infections were caused by gram-negative bacteria and presented early after surgery. Local administration of gentamicin reduced the incidence of SWIs caused by all major, clinically important bacterial species. Propionibacterium acnes was identified as a possible cause of SWI and may be linked to instability in the sternal fixation. There was no indication of an increase in the occurrence of gentamicin-resistant bacterial isolates in the treatment group. Furthermore, the addition of local collagen-gentamicin reduced the incidence of SWIs caused by methicillin-resistant coagulase-negative staphylococci. This technique warrants further evaluation as an alternative to prophylactic vancomycin in settings with a high prevalence of methicillin-resistant Staphylococcus aureus.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 26494
Typ av publikation
tidskriftsartikel (20232)
konferensbidrag (2108)
doktorsavhandling (2004)
forskningsöversikt (813)
bokkapitel (791)
annan publikation (148)
visa fler...
rapport (137)
bok (120)
samlingsverk (redaktörskap) (57)
licentiatavhandling (44)
recension (21)
proceedings (redaktörskap) (12)
patent (7)
konstnärligt arbete (1)
visa färre...
Typ av innehåll
refereegranskat (21275)
övrigt vetenskapligt/konstnärligt (4953)
populärvet., debatt m.m. (266)
Författare/redaktör
Lundälv, Jörgen, 196 ... (344)
Groop, Leif (214)
Berglund, Göran (204)
Nilsson, Peter (190)
Gillberg, Christophe ... (162)
Ahren, Bo (147)
visa fler...
Blennow, Kaj, 1958 (144)
Andersson, Roland (141)
Swedberg, Karl, 1944 (130)
Båth, Magnus, 1974 (129)
Bruze, Magnus (121)
Olsson, Håkan (120)
Johnell, Olof (118)
Borg, Åke (117)
Berntorp, Erik (115)
Edvinsson, Lars (111)
Marsal, Karel (109)
Olsson, Bertil (106)
Wennergren, Göran, 1 ... (105)
Valentin, Lil (105)
Stibrant Sunnerhagen ... (103)
Thomsen, Peter, 1953 (103)
Mattsson, Sören (102)
Lohmander, Stefan (100)
Hedblad, Bo (97)
Söderfeldt, Björn (96)
Giwercman, Aleksande ... (92)
Renvert, Stefan (90)
Zetterberg, Henrik, ... (89)
Minthon, Lennart (88)
Saxne, Tore (88)
Andersson, Karl Erik (87)
Lilja, Hans (86)
Melander, Olle (86)
Sturfelt, Gunnar (85)
Engström, Gunnar (84)
Janzon, Lars (83)
Torén, Kjell, 1952 (82)
Mertens, Fredrik (82)
Albrektsson, Tomas, ... (81)
Landberg, Göran (80)
Skoog, Ingmar, 1954 (79)
Jeppsson, Bengt (78)
Hallmans, Göran (78)
Månsson, Lars Gunnar ... (78)
Manjer, Jonas (77)
Karlsson, Magnus (77)
Dillner, Joakim (77)
Lernmark, Åke (76)
Samsioe, Göran (76)
visa färre...
Lärosäte
Lunds universitet (13627)
Göteborgs universitet (7136)
Uppsala universitet (2805)
Karolinska Institutet (2781)
Umeå universitet (2268)
Linköpings universitet (1382)
visa fler...
Örebro universitet (1121)
Malmö universitet (870)
Högskolan Kristianstad (322)
Jönköping University (285)
Kungliga Tekniska Högskolan (270)
Chalmers tekniska högskola (253)
Högskolan i Halmstad (221)
Mälardalens universitet (138)
Linnéuniversitetet (138)
Mittuniversitetet (129)
Stockholms universitet (123)
Högskolan i Skövde (120)
Högskolan i Borås (93)
Högskolan Dalarna (65)
Luleå tekniska universitet (64)
Karlstads universitet (60)
Marie Cederschiöld högskola (47)
Högskolan i Gävle (46)
Röda Korsets Högskola (43)
Högskolan Väst (42)
Handelshögskolan i Stockholm (34)
Sveriges Lantbruksuniversitet (25)
Södertörns högskola (22)
Gymnastik- och idrottshögskolan (21)
Blekinge Tekniska Högskola (20)
RISE (17)
Sophiahemmet Högskola (16)
Försvarshögskolan (3)
Stockholms konstnärliga högskola (3)
Nordiska Afrikainstitutet (1)
Konstfack (1)
VTI - Statens väg- och transportforskningsinstitut (1)
visa färre...
Språk
Engelska (24389)
Svenska (1945)
Tyska (44)
Odefinierat språk (18)
Finska (18)
Danska (16)
visa fler...
Spanska (13)
Franska (10)
Ungerska (10)
Norska (5)
Italienska (4)
Portugisiska (4)
Tjeckiska (4)
Ryska (3)
Polska (2)
Isländska (2)
Japanska (2)
Bosniska (2)
Rumänska (1)
Kinesiska (1)
visa färre...
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (26330)
Samhällsvetenskap (659)
Naturvetenskap (370)
Teknik (210)
Humaniora (99)
Lantbruksvetenskap (81)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy